Clinical study of intravenous injecting itraconazole as empirical antifungal therapy for patients with hematological malignancies.
- Author:
Cheng-Wei LUO
1
;
Xin DU
;
Rong GUO
;
Jian-Yu WENG
;
Ze-Sheng LU
;
Sui-Jing WU
Author Information
1. Department of Hematology, Guangdong Provincial Academy of Medical Sciences, Guangzhou, Guangdong Province, China.
- Publication Type:Journal Article
- MeSH:
Adolescent;
Adult;
Aged;
Antifungal Agents;
administration & dosage;
therapeutic use;
Female;
Hematologic Neoplasms;
drug therapy;
Humans;
Injections, Intravenous;
Itraconazole;
administration & dosage;
therapeutic use;
Male;
Middle Aged;
Treatment Outcome;
Young Adult
- From:
Journal of Experimental Hematology
2012;20(4):1000-1004
- CountryChina
- Language:Chinese
-
Abstract:
This study was purposed to investigate the efficacy and safety of intravenous injecting itraconazole (ITCZ) as empirical antifungal therapy in the patients with hematological malignancies. According to recommendation in IDSA guidebook, the patients suffered from fever during neutropenia and inefficacy of treatment using broad-spectrum antibiotics for 4 days should receive intravenous injection of ITCZ as empirical antifungal therapy. The results showed that the overall clinical response rate to ITCZ injection was 62.9% (22/35), and the success rate of achieving composite endpoints was 54.3% (19/35). Mild adverse reactions were observed in 6 patients (17.1%). The injection of ITCZ was stopped in 2 patents (5.7%) due to adverse reaction. Further analysis revealed that the response rate was higher in patients with fever prior to the start of ITCZ within five days than beyond five days (P = 0.031). The response rate was higher in patients with possible invasive fungus infection (IFI) than that in patients with probable and confirmed IFI (P = 0.002). The prophylactic antifungal treatment during neutropenia displayed no significant influence on efficacy of empirical antifungal therapy with itraconazole (P = 0.054). It is concluded that the good efficacy and safety of empirical ITCZ injection for hematological malignancies patients is efficient and safe.
